- US hiring soars past expectations in sign of resilient market
- As EU targets Chinese cars, European rivals sputter
- Top EU court finds against FIFA in key transfer market ruling
- Oil extends gains, Hong Kong stocks resume rally
- 'A man provides': Ukrainian miners send families away as Russia advances
- EU states greenlight extra tariffs on EVs from China
- Hong Kong stocks resume rally, oil dips after Middle East-fuelled surge
- Crude stable after Israel-Iran surge, Hong Kong stocks resume gains
- Hera spacecraft to probe asteroid deflected by defence test
- US dockworkers to head back to work after tentative deal
- After Helene's destruction, North Carolina starts to rebuild
- Dockers end three-day strike at Montreal port
- What next for OpenAI after $157 billion bonanza?
- Israel-Hamas war causes 86-percent dive in Gaza GDP: IMF
- Milan's Morata moves house after Inter-fan town mayor 'violates' privacy
- 'Devastating' storm hits Augusta National but Masters will go on
- Relief in Brazil, Asia over delay to EU deforestation rules
- Oil prices jump, stocks fall on Middle East tensions
- Biden says 'discussing' possible Israeli strikes on Iran oil facilities
- Oil prices rise, stocks fall on Middle East tensions
- Oil rallies, stocks mostly retreat on Middle East tensions
- Phasing out teen smoking could save 1.2 mn lives: study
- 'Welcome relief': Asia producers hail EU deforestation law delay
- Japan PM slated to announce plans for 'happiness index'
- Turkish inflation falls less than expected in September at 49.4%
- Easing inflation lifts profit at UK supermarket Tesco
- Skiing calls on UN climate science to combat melting future
- China wine industry looks to breed climate resilience
- Tokyo rallies on weak yen, Hong Kong drops after surge
- Dutch airline KLM unveils 'firm' cost-cutting measures
- Carpe diem: the Costa Rican women turning fish into fashion
- Senegal looks to aquaculture as fish stocks dwindle
- Will AI one day win a Nobel Prize?
- Climate change, economics muddy West's drive to curb Chinese EVs
- Argentina's Milei vetoes university budget after huge protests
- TotalEnergies plans to grow oil and gas production until 2030
- 2024 Nobels offer glimmer of hope as global crises mount
- Tokyo rallies on weak yen, Hong Kong reverses after surge
- Tunisia readies for vote as incumbent Saied eyes victory
- High childcare costs in US weigh on women's employment
- US voters seek help with crushing childcare costs
- Taiwan shuts down for second day as Typhoon Krathon to land
- Supercharged storms: how climate change amplifies cyclones
- Biden official urges talks as US port strike enters second day
- Huge protests in Argentina over public university cuts
- Rally in oil prices loses steam on mixed day for global stocks
- South America treated to rare 'ring of fire' eclipse
- Biden official says port strike deal not as far as parties think
- Mexico's new president offers apology for 1968 student massacre
- Historic funding round values OpenAI at $157 billion
RBGPF | 100% | 58.93 | $ | |
CMSC | -0.16% | 24.74 | $ | |
CMSD | -0.16% | 24.89 | $ | |
SCS | -1.98% | 12.62 | $ | |
BCC | -0.9% | 138.29 | $ | |
GSK | -2.81% | 38.37 | $ | |
AZN | -2.12% | 77.93 | $ | |
RIO | -1.42% | 69.83 | $ | |
BTI | -2.45% | 35.11 | $ | |
NGG | -2.7% | 66.97 | $ | |
RYCEF | 1.15% | 6.98 | $ | |
RELX | -1.46% | 46.61 | $ | |
BCE | -1.77% | 33.84 | $ | |
JRI | -0.6% | 13.3 | $ | |
VOD | -0.52% | 9.69 | $ | |
BP | 0.28% | 32.46 | $ |
Monkeypox vaccine availability and effectiveness
A smallpox vaccine shown to protect against monkeypox has come under huge global demand, leading health authorities to warn against repeating the unequal distribution seen during the Covid pandemic.
While monkeypox had long been endemic in parts of West and Central Africa, since May there have been outbreaks across the world.
It has caused a scramble for doses of the only authorised vaccine against monkeypox worldwide, which is produced by Danish drug maker Bavarian Nordic.
Here is the current state of play about the vaccine's effectiveness and availability.
- 85% protection 'approximate' -
Called MVA-BN and marketed under the name Jynneos in the United States and Imvanex in Europe, the vaccine was originally developed to fight smallpox.
Both viruses are part of the orthopoxvirus family.
Olivier Schwartz, head of the virus and immunity unit at France's Pasteur Institute, said that the virus proteins for monkeypox and smallpox were 90-95 percent similar.
"So using a very similar vaccine to block it is a proven strategy," he said.
While there is not yet large-scale data on the protection of Bavarian Nordic's vaccine against monkeypox, previous research has suggested it is highly effective.
"The vaccine protection figure of 85 percent dates from field studies in the 1980s and 1990s in DR Congo and is quite approximate," Schwartz said.
He added that studies on healthcare workers in 2018 and experiments on macaques had indicated the vaccine can be effective even after a patient has contracted monkeypox.
And people who had a smallpox vaccine dose before 1980 also have some immunity from monkeypox, though its extent and duration remain uncertain.
Schwartz said that studies during the 2000s found that around 30 percent of those vaccinated two decades earlier still had antibodies against smallpox.
He added that a booster dose would "reactivate cellular immunity, even after 20 to 40 years".
But Yannick Simonin, a virologist at the University of Montpellier, warned that immunity "decreases over time and the persistence of neutralising antibodies against monkeypox has never been evaluated".
- 350,000 doses to 'undisclosed' nation -
Bavarian Nordic partnered with the US health authorities in 2003 and has already delivered 30 million doses to the country.
Since monkeypox started spreading outside of Africa in May, the company has said it will deliver seven million more doses to the United States.
There is a total of around 16 million doses of the vaccine worldwide, mostly in bulk form, meaning it will be months before they are ready to use, according to the World Health Organization.
It has been difficult to determine the exact number of stocks held by countries, which have sometimes declined to reveal numbers -- angering some non-governmental organisations and politicians.
Bavarian Nordic, which can produce up to 30 million doses a year, has also been reticent to reveal where it is sending them.
On Wednesday the company announced it would supply 350,000 doses to an "undisclosed" country in the Asia-Pacific region.
Two other smallpox vaccines, ACAM2000 and LC16, are currently being studied to determine their effectiveness against monkeypox.
The United States currently has more than 100 million doses stockpiled of ACAM2000, but it is believed to cause more side effects than newer-generation vaccines.
Emergent BioSolutions, which makes ACAM2000, told AFP that it can currently produce more than 18 million doses a year -- and could ramp up to 40 million annually if needed.
- 'We want equity' -
Despite being the continent that has long battled monkeypox, Africa has yet to receive any vaccine doses.
There have been more than 3,000 confirmed monkeypox cases in Africa this year, while doctors say around 70 deaths have been linked to the disease.
The WHO has called on countries that do have vaccines to share, urging the world not to repeat the inequality of access to Covid vaccines between rich and poor nations.
Meg Doherty, director of the WHO's global HIV, hepatitis and sexually transmitted infection programmes, said on Sunday that 35 countries have requested access to the monkeypox vaccine.
She told a meeting at the International AIDS Conference in Montreal there was "quite a possible risk" that it was rich countries requesting the doses.
"We want equity," she added.
J.Bondarev--CPN